Vofopitant

Vofopitant

Clinical data
Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name (2S,3S)-N-[(2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl)methyl]-2-phenylpiperidin-3-amine
CAS Number	168266-90-8
PubChem CID	6918331
IUPHAR/BPS	5752
ChemSpider	5293535
Chemical and physical data
Formula	C21H23F3N6O
Molar mass	432.442 g/mol
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C(C=C1)N2C(=NN=N2)C(F)(F)F)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4
InChI InChI=1S/C21H23F3N6O/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3/t17-,19-/m0/s1 Key:XILNRORTJVDYRH-HKUYNNGSSA-N

Vofopitant (GR-205,171) is a drug which acts as an NK₁ receptor antagonist. It has antiemetic effects as with other NK₁ antagonists, and also shows anxiolytic actions in animals. It was trialled for applications such as the treatment of social phobia and post-traumatic stress disorder, but did not prove sufficiently effective to be marketed.